Newsroom

LATEST PUBLICATIONS

Leveraging Standardized MRD Assays to Guide CLL Treatment

2024-01-25T10:44:11-08:00January 25th, 2024|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

2023-04-10T20:22:16-07:00March 23rd, 2023|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

2024-08-02T14:22:45-07:00March 7th, 2023|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

2023-04-10T20:24:04-07:00March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

2022-12-29T21:22:21-08:00November 15th, 2022|

Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System

2025-08-26T08:18:25-07:00June 24th, 2021|

Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China

2026-03-09T18:08:11-07:00June 3rd, 2021|

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

2025-08-26T08:11:34-07:00May 19th, 2020|

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

2021-02-26T19:10:05-08:00May 12th, 2020|

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

2021-11-14T22:08:08-08:00December 5th, 2019|

85th Japan Cancer Association Annual Meeting

Sep 24 – 26, 2026
Kyoto, Japan
Attending

75th JAMT Annual Meeting

Sep 26 – 27, 2026
Makuhari, Japan
Attending

ICCS

Oct 2-6, 2026
Miami, FL
Exhibiting
Visit Conference Website

EA4HP-SH

Oct 3-8, 2026
Berlin, Germany
Exhibiting
Visit Conference Website

World Biomarker & CDx Conference

Oct 5-6, 2026
Boston, MA
Attending
Visit Conference Website

Newsroom

Newsroom

LATEST PUBLICATIONS

Leveraging Standardized MRD Assays to Guide CLL Treatment

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

LATEST PRESS

Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System

Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

CONFERENCES

85th Japan Cancer Association Annual Meeting

75th JAMT Annual Meeting

ICCS

EA4HP-SH

World Biomarker & CDx Conference

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶